DHR.WI Stock Overview
Designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Danaher Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$220.75 |
| 52 Week High | US$220.75 |
| 52 Week Low | US$216.00 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| DHR.WI | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.3% | 4.3% | 2.3% |
| 1Y | n/a | 11.1% | 26.8% |
Return vs Industry: Insufficient data to determine how DHR.WI performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how DHR.WI performed against the US Market.
Price Volatility
| DHR.WI volatility | |
|---|---|
| DHR.WI Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DHR.WI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DHR.WI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 80,000 | Rainer Blair | www.danaher.com |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers.
Danaher Corporation Fundamentals Summary
| DHR.WI fundamental statistics | |
|---|---|
| Market cap | US$157.82b |
| Earnings (TTM) | US$6.30b |
| Revenue (TTM) | US$30.36b |
25.3x
P/E Ratio5.2x
P/S RatioIs DHR.WI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DHR.WI income statement (TTM) | |
|---|---|
| Revenue | US$30.36b |
| Cost of Revenue | US$12.42b |
| Gross Profit | US$17.93b |
| Other Expenses | US$11.64b |
| Earnings | US$6.30b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Oct 24, 2023
| Earnings per share (EPS) | 8.53 |
| Gross Margin | 59.08% |
| Net Profit Margin | 20.74% |
| Debt/Equity Ratio | 38.4% |
How did DHR.WI perform over the long term?
See historical performance and comparison